FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
HealthDay on MSN5d
FDA Approves Wearable Infusion Device for Advanced Parkinson DiseaseThe U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection ...
GlobalData on MSN5d
Supernus wins FDA approval for Parkinson’s pump on fourth trySupernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch. “Continuous ...
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
Get Instant Summarized Text (Gist) The FDA has approved Onapgo, a wearable subcutaneous apomorphine infusion device, for treating motor fluctuations in advanced Parkinson's disease. It offers ...
Sold as Onapgo, this device gives a steady dose of apomorphine – a medicine that helps people with Parkinson’s disease move more easily – under the skin to help manage movement issues and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback